roadrunner wrote:I agree with Beach and the others—this is definitely a big win!
In light of your trial team’s excitement, do you know what their specific innovation(s)/differentiation with this trial’s TIL approach is? Also, did they drop any hints as to whether you’re an outlier in their trial, or are they seeing promising results across the board? (I understand they may keep that close.)
Well…….my Resident’s quote was “We were due for a win around here”.
From my understanding, the approach has much greater success with blood cancers and melanoma than it has had in epithelial cancers.
I put the chances of home run success in my case at around 5% prior to treatment based on my research and coded discussions with a few of the doctors.
I’m nowhere near spiking the football, but I’ll take good news where I can get some.
The approach was very straightforward; lesions resected by vats, extract t cells from lesions, test in vitro for response, multiply/expand tils in lab, reduce immune system to near 0, one infusion of keytruda, infuse tils via port/line, administration of as much interleukin 2 as blood tests advise (3 in my case), neupogen injections, recovery until bloods reach levels that allow you to go home, keytruda infusions every three weeks for a total of four, scans at 6 and 12 weeks.
Happy to answer any questions/fill in anything I missed.